Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis Inc (CDXS) pioneers enzyme engineering solutions for biopharmaceutical manufacturing through its CodeEvolver and ECO Synthesis platforms. This page aggregates all official announcements and developments critical to understanding the company's trajectory.
Investors and industry professionals will find curated updates including earnings reports, strategic partnerships, product launches, and manufacturing innovations. Our collection ensures timely access to material information affecting therapeutic production efficiency.
Key content categories include financial performance disclosures, technology licensing agreements, enzyme optimization breakthroughs, and sustainability initiatives. All updates are sourced directly from verified corporate communications.
Bookmark this page for streamlined tracking of Codexis' advancements in protein engineering and RNA therapeutic manufacturing. Check regularly for developments impacting biotech production economics and pharmaceutical process optimization.
Codexis (NASDAQ: CDXS) announced that Byron Dorgan will retire from its Board of Directors at the 2025 Annual Meeting of Stockholders. Dorgan, who joined the Board in 2011 and served as Chairman from 2021 through 2024, currently chairs the Nominating and Corporate Governance Committee.
Following his departure, Dorgan will continue as a consultant to Codexis for one year. The company will reduce its Board seats from ten to nine. During his tenure, Dorgan contributed to Codexis's transformation into a leading therapeutics manufacturing company, particularly in advancing solutions like the ECO Synthesis platform.
Codexis (NASDAQ: CDXS) has appointed Cynthia Collins to its Board of Directors. Collins, currently serving as Executive Chair and interim CEO of Nutcracker Therapeutics, brings over four decades of pharmaceutical and biotech industry experience. She previously served as CEO of Editas Medicine, where she led the first clinical trial of in vivo CRISPR gene editing therapy.
Collins' extensive leadership experience includes roles as CEO of Human Longevity, various executive positions at GE Healthcare, CEO of GenVec, and president of oncology at Baxter Healthcare. She currently serves on multiple boards including Certara, MaxCyte, and DermTech. The appointment aims to support Codexis' expansion of their ECO Synthesis toolbox in the RNA therapeutics space.
Codexis (NASDAQ: CDXS) has secured its first revenue-generating contract for manufacturing siRNA material using their ECO Synthesis™ Innovation Lab. The company has successfully developed and validated the first generation of core ECO Synthesis™ enzymes, meeting pre-specified criteria for industrial-scale production.
This milestone follows their previous achievements in dsRNA ligation offerings. The company plans to demonstrate process parameters that are comparable to or potentially superior to traditional chemical methods at upcoming scientific meetings.
Codexis (NASDAQ: CDXS) has announced the approval of equity grants for two new employees, as authorized by the company's Compensation Committee. The inducement awards, issued under the 2024 Inducement Plan, include:
- Stock options to purchase 10,000 shares, with an exercise price matching Codexis' Nasdaq closing price on the grant date
- 5,000 restricted stock units (RSUs)
The stock options vest over four years, with 25% vesting after the first year and the remainder vesting monthly thereafter. The RSUs will vest in equal annual installments over three years. Both grants require continued employment with Codexis through applicable vesting dates.
Codexis (NASDAQ: CDXS) reported financial results for Q4 and FY 2024, with total revenue of $59.3 million for the fiscal year, representing a 4% decrease from 2023. Product revenues increased 6% to $36.8 million, while R&D revenues were $22.6 million.
The company reported a net loss of $65.3 million ($0.89 per share) for FY 2024, improved from a $76.2 million loss in 2023. Cash position stands at $73.5 million as of December 31, 2024, bolstered by $31 million raised via ATM facility.
For 2025, Codexis expects:
- Total revenues between $64-68 million
- Double-digit growth in total revenue
- Acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material
- Securing a GMP scale-up partner
Codexis (NASDAQ: CDXS), a leading enzymatic solutions provider for therapeutics manufacturing, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The conference will take place from March 3-5, 2025, in Boston, Massachusetts.
The company's management will engage in a fireside chat on Tuesday, March 4, 2025, at 1:10 pm ET. Investors and interested parties can access a live webcast of the presentation through the Investor Relations section of Codexis's website at https://ir.codexis.com. The presentation recording will remain available for replay on the website for 90 days after the event.
Codexis (NASDAQ: CDXS) has announced the approval of equity grants for five new employees, as approved by the company's Board of Directors' Compensation Committee. The inducement awards, granted under the 2024 Inducement Plan, include:
Stock Options: 39,000 shares with an exercise price matching Codexis' Nasdaq closing price on grant date. These vest over four years, with 25% vesting after one year and the remainder vesting monthly.
Restricted Stock Units (RSUs): 27,500 units vesting in equal annual installments over three years. Both grants are subject to continued employment with Codexis through applicable vesting dates.
Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss financial results and provide a business update.
The webcast will be available on the Codexis Investor Relations website and archived for 90 days. Investors can access the live call by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will be available at 877-660-6853 (domestic) or 201-612-7415 (international) with access ID #13726635.
Codexis (NASDAQ: CDXS) has appointed Arthur Levin, PhD to its Strategic Advisory Board. Dr. Levin, a founding member of Avidity Biosciences and current board member, brings three decades of oligonucleotide development experience to support Codexis's ECO Synthesis™ manufacturing platform growth.
Dr. Levin's extensive background includes being the first to develop approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He previously served as Distinguished Scientist, Strategic Leader, and Chief Scientific Officer at Avidity, and held senior development roles at miRagen Therapeutics, Ionis Pharmaceuticals, and Santaris Pharmaceuticals.
With over 100 scientific publications and several highly-cited reviews in the field, Dr. Levin will provide strategic guidance to Codexis as it expands its RNAi therapeutics capabilities through enzymatic technologies.
Codexis (NASDAQ: CDXS) has appointed Christos Richards to its Board of Directors. Richards brings over 30 years of global executive advisory and search experience in the biopharmaceutical and healthcare industry. He currently serves as Global Head of Healthcare and Life Sciences at Calibre One and has completed more than 450 executive level assignments, including over 200 Board, CEO, and CEO succession projects.
Richards currently leads Calibre One's healthcare and life sciences practice, serving clients from venture-backed startups to global enterprises. His experience spans devices, diagnostics, agricultural biotechnology, animal health, tools, services, and digital health sectors. He previously served on the Board of Directors for Coherus BioSciences and is an advisor for the UCSF Innovation Ventures Entrepreneurship Center.
